Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.54 |
| ▸ | CPS1 | P31327 | 4/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | KAT7 | O95251 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4418322 | 0.92 | USP30 (0.47) | USP30KRASSETD7KAT7DPP4 | |
| SCHEMBL4415927 | 0.89 | KAT7 (0.44) | USP30CPS1SETD7KAT7SCN9A | |
| SCHEMBL4408769 | 0.88 | USP30 (0.47) | USP30CPS1KAT7PARP1 | |
| SCHEMBL12832455 | 0.88 | NR1H2 (0.45) | USP30CPS1SETD7KAT7DPP4 | |
| SCHEMBL24558073 | 0.88 | USP30 (0.43) | USP30SETD7KAT7DPP4TRPV3 | |
| SCHEMBL29046811 | 0.88 | USP30 (0.43) | USP30SETD7KAT7DPP4TRPV3 | |
| SCHEMBL24558215 | 0.87 | USP30 (0.41) | USP30CPS1SETD7KAT7DPP4 | |
| SCHEMBL4407351 | 0.85 | GPR119 (0.43) | KAT7PARP1 | |
| SCHEMBL1498908 | 0.85 | GPR119 (0.49) | USP30CPS1KAT7 | |
| SCHEMBL12780724 | 0.85 | GPR119 (0.49) | USP30CPS1KAT7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | USP30 4369/4885CPS1 2888/4885KRAS 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.